ANA Presentation at CTAD 2020
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Thanks to the latest research, we can now target specific migraine pathways.
Infusion therapy may seem modern, but its origins trace as far back as 1492.
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Your health is our top priority and we want to ensure that you are accessing — and not delaying — the care you need.
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
The field of epilepsy has seen great strides in the last couple of decades.
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”